Header for print stylesheet
You are here:  
DSM Pharmaceuticals Inc. Announces New Fill-Finish Service Capabilities for Injectable Cytotoxic Products
Parsippany,USA,28-Sep-2007

DSM Pharmaceuticals Inc., a leading global provider of aseptic manufacturing and development services to the pharmaceutical and biopharmaceutical industries, announces today the addition of aseptic fill-finish manufacturing services for injectable cytotoxic products. The facility will be ready for commercial production in January.

Aseptic Cytotoxic capabilities include flexible commercial scale fill-finish services for liquid and lyophilized products in vial sizes up to 65ml. The dedicated suites use RABS systems to ensure product isolation and include a TL filler and a BOC Edwards freeze dryer. 

“As a recognized leader in aseptic manufacturing services, with innovations such as Lyo-Advantage and Liquid Advantage, DSM now brings their experience and knowledge to the next level with the addition of Cytotoxic fill-finish services,” says Terry Novak, President, DSM Pharmaceuticals Inc. “The market for injectable cytotoxic products is expected to grow at double-digit levels over the next 5 years as evidenced by the number of customers interested in our Cytotoxic capabilities.”

About DSM Pharmacueticals Inc.
DSM Pharmaceuticals, Inc. a business unit of DSM Pharmaceutical Products, is a global provider of custom manufacturing services to the pharmaceutical and biopharmaceutical industries. Our breadth of manufacturing services include the areas of steriles, orals and topicals, including dose form manufacturing, scheduled drugs, clinical manufacturing, fill finish manufacturing, and lyophilization services.

About DSM Pharmaceutical Products
DSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing services to the pharmaceutical and biopharmaceutical industries. DSM Pharmaceutical Products provides contract manufacturing services including: advanced intermediates, active ingredients (API's), amino acids and derivatives, mammalian cell culture production (fed-batch and perfusion) of monoclonal antibodies, proteins, vaccines, finished dose manufacturing of solid dose, scheduled drugs, liquids, aseptic liquid and lyophilized products.
From clinical to commercial services, DSM focuses the right resources on providing the highest level of service and quality while applying innovative solutions to satisfy customers’ unique manufacturing needs.

PDF Version (27.5Kb)

Pdf document
For more information
DSM Pharmaceutical Products
+1-973-257-8471
Terry.Novak@dsm.com
footer for print stylesheet